Latest News & Features
Big Pharma
An Advocate General in the Court of Justice of the European Union, Niilo Jääskinen, has clarified how the regulation for supplementary protection certificates should be interpreted concerning medicinal products made with a combination of active ingredients. 2 October 2015
Big Pharma
The CJEU’s decision in Forsgren has brought greater clarity to the scope of the SPC regulation, including whether a substance is an active ingredient, as Avi Toltzis and Penny Gilbert of Powell Gilbert explain. 1 October 2015
Big Pharma
The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports. 1 October 2015
Europe
An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing. 1 October 2015
Big Pharma
The Warner-Lambert v Actavis case concerning second medical use patents has resulted in a carefully considered judgment and there are some clear lessons to be learnt, says Arty Rajendra of Rouse Legal. 1 October 2015
Africa
The international police organisation Interpol plays a vital role in connecting law enforcement and health authorities around the world in the fight against pharmaceutical crime. Aline Plançon reports. 1 October 2015
Big Pharma
An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing. 24 September 2015
Americas
Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report. 17 September 2015
Americas
Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology. 17 September 2015
Big Pharma
Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows. 10 September 2015